Cardioprotective effects of remimazolam in elderly hypertensive patients undergoing gastrointestinal tumor surgery: A randomized controlled trial

Table 1 Comparison of baseline characteristics between the two groups, mean ± SD/n (%)

Item	P group (n = 40)	R group (n = 40)	χ2/t value	P value
Sex			2.650	0.104
Male	29 (72.50)	22 (55.00)
Female	11 (27.50)	18 (45.00)
Age (years)	73.90 ± 8.03	70.83 ± 6.70	1.859	0.067
ASA classification			2.257	0.133
II	8 (20.00)	14 (35.00)
III	32 (80.00)	26 (65.00)
Height (cm)	165.98 ± 6.73	164.73 ± 6.72	0.831	0.409
Weight (kg)	64.46 ± 9.59	64.74 ± 10.41	-0.123	0.903
BMI (kg/m2)	23.30 ± 2.99	23.80 ± 3.25	-0.713	0.478
Tumor type			5.137	0.162
Colon cancer	11 (27.50)	20 (50.00)
Rectal cancer	13 (32.50)	8 (20.00)
Gastric cancer	15 (37.50)	12 (30.00)
Gastrointestinal stromal tumor	1 (2.50)	0 (0.00)
Comorbidities
Cerebral infarction	7 (17.50)	4 (10.00)	0.949	0.330
Diabetes mellitus	6 (15.00)	10 (25.00)	1.250	0.264
Coronary heart disease	2 (5.00)	1 (2.50)	0.000	1.000
Others	5 (12.50)	3 (7.50)	0.139	0.709

P group: Control group (propofol-based intravenous general anesthesia); R group: Experimental group (remimazolam-based intravenous general anesthesia); ASA: American Society of Anesthesiologists; BMI: Body mass index.